SEP 23, 2016 9:00 AM PDT

Access key technologies to accelerate genetic testing in your laboratory

Sponsored by: Natera, Natera
Speaker
  • Field Application Scientist Natera, Inc.
    Biography
      Samuel Suk received an M.S. in bioengineering from UCSD in La Jolla, California. Subsequently, he has held scientific support positions at Thermo Fisher and Fluidigm working with customers from a wide variety of industries. Currently, Samuel is a Field Application Scientist with Natera providing technical assistance worldwide to labs that are pursuing Panorama NIPT implementation.

    Abstract
    DATE: September 23, 2016
    TIME:   9:00 AM PST, 12:00 PM ET

     
    As genetic testing becomes more pervasive, many clinical and pathology laboratories see next generation sequencing (NGS) as an attractive evolution of their lab’s testing capabilities. There is already precedent for reimbursement by private and public insurers for genetic testing, particularly NGS genetic testing. However the decision to choose a genetic test that has a large market potential, is reimbursable (or willingly paid for out-of-pocket), and is easy to implement is daunting. One such test that meets all three business needs is the non-invasive prenatal test (NIPT). NIPT is applicable to a very large market (ca. 136.8M births per year globally). It is reimbursed by more private or government insurance and is readily paid for by consumers directly. The test is now easily implemented in most laboratories through Natera’s technology licensing program. Natera has invested 10s of millions of dollars in research and development and makes these technologies available to licensees under its technology licensing program. By licensing from Natera, laboratories can access some of the same technologies employed for Natera’s Panorama NIPT. This includes key Natera reagents, bioinformatics algorithms, and scientific resources used to develop a powerful NIPT offering. This webinar will introduce Natera’s technology licensing program and explain the process in which prospective licensee labs may license key Natera technology to perform NIPT in their own labs thereby offering a market leading NIPT in their own market.

    *Only available in certain geographies. Talk with your local representative for availability in your country*

     

    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    APR 27, 2020 9:00 AM PDT
    C.E. CREDITS
    APR 27, 2020 9:00 AM PDT
    DATE: April 27, 2020 TIME: 9:00am PT, 12:00pm ET Recombinant adeno-associated virus (rAAV) is a small (25-nm) virus that is composed of a protein shell called a capsid and a single-stranded...
    MAY 04, 2020 9:00 AM PDT
    C.E. CREDITS
    MAY 04, 2020 9:00 AM PDT
    DATE: May 4, 2020 TIME: 9:00am PT, 12:00pm ET...
    Loading Comments...
    Show Resources
    Attendees
    • See more